|
||||
Public Act 096-0967 |
||||
| ||||
| ||||
AN ACT concerning insurance.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Health Carrier External Review Act is | ||||
amended by changing Section 35 as follows: | ||||
(215 ILCS 180/35) | ||||
(This Section may contain text from a Public Act with a | ||||
delayed effective date )
| ||||
Sec. 35. Standard external review. | ||||
(a) Within 4 months after the date of receipt of a notice | ||||
of an adverse determination or final adverse determination, a | ||||
covered person or the covered person's authorized | ||||
representative may file a request for an external review with | ||||
the health carrier. | ||||
(b) Within 5 business days following the date of receipt of | ||||
the external review request, the health carrier shall complete | ||||
a preliminary review of the request to determine whether:
| ||||
(1) the individual is or was a covered person in the | ||||
health benefit plan at the time the health care service was | ||||
requested or at the time the health care service was | ||||
provided; | ||||
(2) the health care service that is the subject of the | ||||
adverse determination or the final adverse determination |
is a covered service under the covered person's health | ||
benefit plan, but the health carrier has determined that | ||
the health care service is not covered because it does not | ||
meet the health carrier's requirements for medical | ||
necessity, appropriateness, health care setting, level of | ||
care, or effectiveness; | ||
(3) the covered person has exhausted the health | ||
carrier's internal grievance process as set forth in this | ||
Act; | ||
(4) for appeals relating to a determination based on | ||
treatment being experimental or investigational, the | ||
requested health care service or treatment that is the | ||
subject of the adverse determination or final adverse | ||
determination is a covered benefit under the covered | ||
person's health benefit plan except for the health | ||
carrier's determination that the service or treatment is | ||
experimental or investigational for a particular medical | ||
condition and is not explicitly listed as an excluded | ||
benefit under the covered person's health benefit plan with | ||
the health carrier and that the covered person's health | ||
care provider, who ordered or provided the services in | ||
question and who is licensed under the
Medical Practice Act | ||
of 1987 is a physician licensed to practice medicine in all | ||
its branches , has certified that one of the following | ||
situations is applicable: | ||
(A) standard health care services or treatments |
have not been effective in improving the condition of | ||
the covered person; | ||
(B) standard health care services or treatments | ||
are not medically appropriate for the covered person; | ||
(C) there is no available standard health care | ||
service or treatment covered by the health carrier that | ||
is more beneficial than the recommended or requested | ||
health care service or treatment;
| ||
(D) the health care service or treatment is likely | ||
to be more beneficial to the covered person, in the | ||
health care provider's opinion, than any available | ||
standard health care services or treatments; or | ||
(E) that scientifically valid studies using | ||
accepted protocols demonstrate that the health care | ||
service or treatment requested is likely to be more | ||
beneficial to the covered person than any available | ||
standard health care services or treatments; and | ||
(5) the covered person has provided all the information | ||
and forms required to process an external review, as | ||
specified in this Act. | ||
(c) Within one business day after completion of the | ||
preliminary review, the health carrier shall notify the covered | ||
person and, if applicable, the covered person's authorized | ||
representative in writing whether the request is complete and | ||
eligible for external review. If the request: | ||
(1) is not complete, the health carrier shall inform |
the covered person and, if applicable, the covered person's | ||
authorized representative in writing and include in the | ||
notice what information or materials are required by this | ||
Act to make the request complete; or | ||
(2) is not eligible for external review, the health | ||
carrier shall inform the covered person and, if applicable, | ||
the covered person's authorized representative in writing | ||
and include in the notice the reasons for its | ||
ineligibility.
| ||
The notice of initial determination of ineligibility shall | ||
include a statement informing the covered person and, if | ||
applicable, the covered person's authorized representative | ||
that a health carrier's initial determination that the external | ||
review request is ineligible for review may be appealed to the | ||
Director by filing a complaint with the Director. | ||
Notwithstanding a health carrier's initial determination | ||
that the request is ineligible for external review, the | ||
Director may determine that a request is eligible for external | ||
review and require that it be referred for external review. In | ||
making such determination, the Director's decision shall be in | ||
accordance with the terms of the covered person's health | ||
benefit plan and shall be subject to all applicable provisions | ||
of this Act. | ||
(d) Whenever a request is eligible for external review the | ||
health carrier shall, within 5 business days: | ||
(1) assign an independent review organization from the |
list of approved independent review organizations compiled | ||
and maintained by the Director; and | ||
(2) notify in writing the covered person and, if | ||
applicable, the covered person's authorized representative | ||
of the request's eligibility and acceptance for external | ||
review and the name of the independent review organization. | ||
The health carrier shall include in the notice provided to | ||
the covered person and, if applicable, the covered person's | ||
authorized representative a statement that the covered person | ||
or the covered person's authorized representative may, within 5 | ||
business days following the date of receipt of the notice | ||
provided pursuant to item (2) of this subsection (d), submit in | ||
writing to the assigned independent review organization | ||
additional information that the independent review | ||
organization shall consider when conducting the external | ||
review. The independent review organization is not required to, | ||
but may, accept and consider additional information submitted | ||
after 5 business days. | ||
(e) The assignment of an approved independent review | ||
organization to conduct an external review in accordance with | ||
this Section shall be made from those approved independent | ||
review organizations qualified to conduct external review as | ||
required by Sections 50 and 55 of this Act. | ||
(f) Upon assignment of an independent review organization, | ||
the health carrier or its designee utilization review | ||
organization shall, within 5 business days, provide to the |
assigned independent review organization the documents and any | ||
information considered in making the adverse determination or | ||
final adverse determination; in such cases, the following | ||
provisions shall apply: | ||
(1) Except as provided in item (2) of this subsection | ||
(f), failure by the health carrier or its utilization | ||
review organization to provide the documents and | ||
information within the specified time frame shall not delay | ||
the conduct of the external review. | ||
(2) If the health carrier or its utilization review | ||
organization fails to provide the documents and | ||
information within the specified time frame, the assigned | ||
independent review organization may terminate the external | ||
review and make a decision to reverse the adverse | ||
determination or final adverse determination. | ||
(3) Within one business day after making the decision | ||
to terminate the external review and make a decision to | ||
reverse the adverse determination or final adverse | ||
determination under item (2) of this subsection (f), the | ||
independent review organization shall notify the health | ||
carrier, the covered person and, if applicable, the covered | ||
person's authorized representative, of its decision to | ||
reverse the adverse determination. | ||
(g) Upon receipt of the information from the health carrier | ||
or its utilization review organization, the assigned | ||
independent review organization shall review all of the |
information and documents and any other information submitted | ||
in writing to the independent review organization by the | ||
covered person and the covered person's authorized | ||
representative. | ||
(h) Upon receipt of any information submitted by the | ||
covered person or the covered person's authorized | ||
representative, the independent review organization shall | ||
forward the information to the health carrier within 1 business | ||
day. | ||
(1) Upon receipt of the information, if any, the health | ||
carrier may reconsider its adverse determination or final | ||
adverse determination that is the subject of the external | ||
review.
| ||
(2) Reconsideration by the health carrier of its | ||
adverse determination or final adverse determination shall | ||
not delay or terminate the external review.
| ||
(3) The external review may only be terminated if the | ||
health carrier decides, upon completion of its | ||
reconsideration, to reverse its adverse determination or | ||
final adverse determination and provide coverage or | ||
payment for the health care service that is the subject of | ||
the adverse determination or final adverse determination. | ||
In such cases, the following provisions shall apply: | ||
(A) Within one business day after making the | ||
decision to reverse its adverse determination or final | ||
adverse determination, the health carrier shall notify |
the covered person and if applicable, the covered | ||
person's authorized representative, and the assigned | ||
independent review organization in writing of its | ||
decision. | ||
(B) Upon notice from the health carrier that the | ||
health carrier has made a decision to reverse its | ||
adverse determination or final adverse determination, | ||
the assigned independent review organization shall | ||
terminate the external review. | ||
(i) In addition to the documents and information provided | ||
by the health carrier or its utilization review organization | ||
and the covered person and the covered person's authorized | ||
representative, if any, the independent review organization, | ||
to the extent the information or documents are available and | ||
the independent review organization considers them | ||
appropriate, shall consider the following in reaching a | ||
decision: | ||
(1) the covered person's pertinent medical records; | ||
(2) the covered person's health care provider's | ||
recommendation; | ||
(3) consulting reports from appropriate health care | ||
providers and other documents submitted by the health | ||
carrier, the covered person, the covered person's | ||
authorized representative, or the covered person's | ||
treating provider; | ||
(4) the terms of coverage under the covered person's |
health benefit plan with the health carrier to ensure that | ||
the independent review organization's decision is not | ||
contrary to the terms of coverage under the covered | ||
person's health benefit plan with the health carrier; | ||
(5) the most appropriate practice guidelines, which | ||
shall include applicable evidence-based standards and may | ||
include any other practice guidelines developed by the | ||
federal government, national or professional medical | ||
societies, boards, and associations; | ||
(6) any applicable clinical review criteria developed | ||
and used by the health carrier or its designee utilization | ||
review organization; and | ||
(7) the opinion of the independent review | ||
organization's clinical reviewer or reviewers after | ||
considering items (1) through (6) of this subsection (i) to | ||
the extent the information or documents are available and | ||
the clinical reviewer or reviewers considers the | ||
information or documents appropriate; and | ||
(8) for a denial of coverage based on a determination | ||
that the health care service or treatment recommended or | ||
requested is experimental or investigational, whether and | ||
to what extent: | ||
(A) the recommended or requested health care | ||
service or treatment has been approved by the federal | ||
Food and Drug Administration, if applicable, for the | ||
condition; |
(B) medical or scientific evidence or | ||
evidence-based standards demonstrate that the expected | ||
benefits of the recommended or requested health care | ||
service or treatment is more likely than not to be | ||
beneficial to the covered person than any available | ||
standard health care service or treatment and the | ||
adverse risks of the recommended or requested health | ||
care service or treatment would not be substantially | ||
increased over those of available standard health care | ||
services or treatments; or | ||
(C) the terms of coverage under the covered | ||
person's health benefit plan with the health carrier to | ||
ensure that the health care service or treatment that | ||
is the subject of the opinion is experimental or | ||
investigational would otherwise be covered under the | ||
terms of coverage of the covered person's health | ||
benefit plan with the health carrier. | ||
(j) Within 5 days after the date of receipt of all | ||
necessary information, the assigned independent review | ||
organization shall provide written notice of its decision to | ||
uphold or reverse the adverse determination or the final | ||
adverse determination to the health carrier, the covered person | ||
and, if applicable, the covered person's authorized | ||
representative. In reaching a decision, the assigned | ||
independent review organization is not bound by any claim | ||
determinations reached prior to the submission of information |
to the independent review organization. In such cases, the | ||
following provisions shall apply: | ||
(1) The independent review organization shall include | ||
in the notice: | ||
(A) a general description of the reason for the | ||
request for external review; | ||
(B) the date the independent review organization | ||
received the assignment from the health carrier to | ||
conduct the external review; | ||
(C) the time period during which the external | ||
review was conducted; | ||
(D) references to the evidence or documentation, | ||
including the evidence-based standards, considered in | ||
reaching its decision; | ||
(E) the date of its decision; and | ||
(F) the principal reason or reasons for its | ||
decision, including what applicable, if any, | ||
evidence-based standards that were a basis for its | ||
decision.
| ||
(2) For reviews of experimental or investigational | ||
treatments, the notice shall include the following | ||
information: | ||
(A) a description of the covered person's medical | ||
condition; | ||
(B) a description of the indicators relevant to | ||
whether there is sufficient evidence to demonstrate |
that the recommended or requested health care service | ||
or treatment is more likely than not to be more | ||
beneficial to the covered person than any available | ||
standard health care services or treatments and the | ||
adverse risks of the recommended or requested health | ||
care service or treatment would not be substantially | ||
increased over those of available standard health care | ||
services or treatments; | ||
(C) a description and analysis of any medical or | ||
scientific evidence considered in reaching the | ||
opinion; | ||
(D) a description and analysis of any | ||
evidence-based standards; | ||
(E) whether the recommended or requested health | ||
care service or treatment has been approved by the | ||
federal Food and Drug Administration, for the | ||
condition; | ||
(F) whether medical or scientific evidence or | ||
evidence-based standards demonstrate that the expected | ||
benefits of the recommended or requested health care | ||
service or treatment is more likely than not to be more | ||
beneficial to the covered person than any available | ||
standard health care service or treatment and the | ||
adverse risks of the recommended or requested health | ||
care service or treatment would not be substantially | ||
increased over those of available standard health care |
services or treatments; and | ||
(G) the written opinion of the clinical reviewer, | ||
including the reviewer's recommendation as to whether | ||
the recommended or requested health care service or | ||
treatment should be covered and the rationale for the | ||
reviewer's recommendation. | ||
(3) In reaching a decision, the assigned independent | ||
review organization is not bound by any decisions or | ||
conclusions reached during the health carrier's | ||
utilization review process or the health carrier's | ||
internal grievance or appeals process. | ||
(4) Upon receipt of a notice of a decision reversing | ||
the adverse determination or final adverse determination, | ||
the health carrier immediately shall approve the coverage | ||
that was the subject of the adverse determination or final | ||
adverse determination.
| ||
(Source: P.A. 96-857, eff. 7-1-10.)
| ||
Section 95. No acceleration or delay. Where this Act makes | ||
changes in a statute that is represented in this Act by text | ||
that is not yet or no longer in effect (for example, a Section | ||
represented by multiple versions), the use of that text does | ||
not accelerate or delay the taking effect of (i) the changes | ||
made by this Act or (ii) provisions derived from any other | ||
Public Act.
|